Study record · Thymosin alpha-1
ETASS: thymosin alpha-1 for severe sepsis
Mortality was 26.0% versus 35.0%; RR 0.74 (95% CI 0.54-1.02), with borderline/mixed significance depending on analysis; mHLA-DR improved.
Key result
Mortality was 26.0% versus 35.0%; RR 0.74 (95% CI 0.54-1.02), with borderline/mixed significance depending on analysis; mHLA-DR improved.
Study details
Study designMulticenter randomized controlled trial; single-blind
PopulationAdults with severe sepsis
Sample size361
RouteSubcutaneous
Regimen / exposureThymosin alpha-1 added to standard care; exact regimen per trial protocol
Duration28 days
ComparatorControl
Primary endpoint / question28-day all-cause mortality and immune markers
Safety resultNo definitive large-trial safety conclusion.
Key limitationsEarlier smaller trial; mortality estimate crossed 1.0 and later larger TESTS trial was negative.
Registry / identifierPMID 23327199